Innovent Biologics is the Suzhou-based Chinese pharmaceutical company behind mazdutide, the once-weekly GLP-1/glucagon dual receptor agonist it licensed from Eli Lilly and has driven to Chinese registration. Mazdutide carries China's first homegrown incretin approval and anchors a broader cardiometabolic pipeline of next-generation peptides.
The Phase 3 GLORY program is the data engine. GLORY-1 supported Innovent's China obesity filing, and GLORY-2, presented at ADA 2026 on June 7, showed mazdutide 9 mg producing up to 20.1% weight loss in Chinese adults with obesity. The DREAMS-3 head-to-head trial against semaglutide in Chinese adults with type 2 diabetes hit a composite primary endpoint of HbA1c under 7% plus at least 10% weight loss in 48.0% of mazdutide patients versus 21.0% on semaglutide. China's NMPA approved mazdutide for obesity in 2025, making Innovent the first Asian incretin sponsor to reach commercial scale.
Stories here cover mazdutide trial readouts, regulatory milestones, and Innovent's broader metabolic pipeline. See #mazdutide, #glory-2, and #dreams-3 for adjacent threads.
At ADA 2026 on Sunday June 7, Innovent presented the Phase 3 GLORY-2 trial of mazdutide 9 mg in Chinese adults with obesity, presented by Leili Gao of Peking University People's Hospital. The dual GLP-1/glucagon agonist drove up to 20.1% mean weight loss and met its primary endpoint and all key secondary endpoints. The result extends China's homegrown obesity-peptide leadership, with mazdutide already approved by China's NMPA in 2025.
Innovent's DREAMS-3 Phase 3b head-to-head trial of mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity was presented Sunday June 7 by Linong Ji of Peking University People's Hospital. On the composite primary endpoint, 48.0% of mazdutide-treated patients reached HbA1c under 7% plus at least 10% body weight reduction versus 21.0% on semaglutide. The readout is the first Phase 3 head-to-head defeat for semaglutide outside Lilly's tirzepatide series.
Innovent Biologics announced May 12 that it will present multiple clinical and preclinical results from mazdutide and its next-generation obesity & metabolic pipeline at the 2026 American Diabetes Association Scientific Sessions in New Orleans, June 5-8. Mazdutide is a GLP-1/glucagon dual agonist developed initially for the Chinese market. The Phase 3 GLORY-2 trial in Chinese adults with moderate-to-severe obesity reported a mean 18.55% weight reduction at 60 weeks on 9 mg dosing (vs ~3% placebo); 44% of GLORY-2 patients hit ≥20% body weight loss vs 2.5% on placebo. The Phase 3 head-to-head DREAMS-3 trial in T2D + obesity showed 48% of mazdutide patients hit HbA1c <7% + ≥10% weight loss vs 21% on semaglutide at week 32. The 9 mg dose is under NMPA review for approval in China. Mazdutide is the leading non-Lilly dual GLP-1/glucagon program competing with Boehringer's survodutide and earlier-stage Western programs.